PRF1 and colonic neoplasm: Consistent with this strategy, the inhibition of glycogen synthase kinase-3β with TWS119 inhibitor, boost proliferation, differentiation, and cytolytic activity of γδ T cells against colon cancer cells, activating mammalian target rapamycin (mTOR) pathway and upregulating the antiapoptotic protein Bcl-2 as well as the expression of perforin and granzyme B in vitro and in vivo (59).